Value Dossier Icon

About Christian Schneider

This author has not yet filled in any details.
So far Christian Schneider has created 20 blog entries.

Pharmabarometer Update

Have a look at our latest update of German price negotiations for drugs that went through the AMNOG benefit assessment. The mean price decrease after negotiations was 28 % for all analysed products, 23 % for orphan drugs and 30 % for non-orphan drugs. If you have any further questions or suggestions, please feel free

2022-08-23T09:27:36+02:0023. August 2022|Reimbursement|0 Comments

GKV-FinStG cabinet decision: Power shift in favor of the statutory health insurance companies expected

The German cabinet, the coalition group of ministers,  has decided to introduce the draft bill on the financial stabilization of the statutory health insurance (GKV-FinStG) into the parliamentary process [GKV-Finanzstabilisierungsgesetz - Bundesgesundheitsministerium]. The subjects of the draft bill are amendments to the Social Code Book V, in particular sections § 35a and § 130b, which

GKV-FinStG draft law: The status of the comparator will impact the outcome of price negotiations

Recently, the German Federal Ministry of Health has published a draft law on the financial stabilization of the statutory health insurance (GKV-FinStG). In the following figure, we have summarized the newly proposed negotiation terms. The draft law intends for a stricter regulation of price negotiations following benefit assessments depending on the status of the most

GKV-FinStG draft law: Power shift in favor of the statutory health insurance companies expected

The German Federal Ministry of Health has published a draft law on the financial stabilization of the statutory health insurance (GKV-FinStG). The subjects of the draft are amendments to the Social Code Book V, in particular Articles § 35 a and § 130 b, which include the early benefit assessment of new active substances and

Challenges and Chances of the EU-HTA

The first medicinal products used to treat oncologic diseases and ATMPs will be assessed within the framework of the Joint Clinical Assessments on the level of the European Union (EU) starting in 2025. Until then, the necessary health technology assessment (HTA) process needs to be defined and refined. Today, we were honored to present our

2022-04-05T15:02:46+02:0023. February 2022|European HTA|0 Comments

EU-HTA: Regulation 2021/2282 is effective starting today

The Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment (HTA) and amending Directive 2011/24/EU is effective starting today, 11 January 2022. Click for more information>>> The Regulation aims to establish joint clinical assessments of health technologies in the European Union (EU) starting with oncologic

2022-04-05T15:02:46+02:0011. January 2022|European HTA, HTA Services|0 Comments

EU-HTA: Adoption of the Regulation

On Dec 13th, 2021, the Regulation on Health Technology Assessment (HTA) has officially been adopted. The new Regulation aims to establish a system for joint clinical assessments of health technologies in the European Union. First assessments of oncologic drugs and ATMPs start in 2025, followed by orphan drugs three years later in 2028 and medicinal

2022-04-05T15:02:46+02:0021. December 2021|European HTA, HTA Services|0 Comments

EUnetHTA 21 – Open call for Joint Scientific Consultations

This month, the European Council adopted the regulation on the EU-wide assessment of health technologies (EU-HTA). At the same time, the first call for applications is now open for scientific advice within the framework of EUnetHTA. In the open call of the EUnetHTA 21 JSC Secretariat, pharmaceutical companies can apply for parallel consultations with the

2022-04-05T15:02:46+02:0017. November 2021|European HTA|0 Comments
Go to Top